The search for a safe and effective method of contraception has been ongoing for centuries. During the last century, a variety of hormonal contraceptives, including combined hormonal oral contraceptives (COCs), have been introduced into the market. COCs have evolved through modifications of different hormonal components to minimize the risk of thrombotic events including stroke, myocardial infarction, and venous thrombosis. The evolution of COC development led to the reduction in the estrogen dose, in an attempt to lower the risk of vascular diseases. Although the risk of thrombotic events due to COC use has been substantially reduced since their inception, the quest for developing safer methods of birth control continues. It is of great interest to study coagulation effects of newer COCs, as well as progestin only, as rigorously as older COCs.
Introduction

Discovery of Hormonal Contraceptives
The search for a safe and efficient method for pregnancy prevention has been a continuous effort for centuries. Until modern times and the advent of hormonal contraception, birth control practice unsuccessfully relied on methods such as herbal remedies, rituals, prolonged breast-feeding, coitus interruptus, the use of heavy metals (lead, arsenic, and mercury), intrauterine devices, and sterilization practices using rudimentary agents such as ivy, willow, and hawthorn. 1, 2 The transition to a more successful era of contraception began with the invention of the condom. First suggested in 1564 by Gabriel Fallopius, the condom was actually developed in 1709 by a physician of King Charles II, as means of protection against syphilis. 2, 3 The condom became a very popular method of birth control due its simplicity, availability, and effectiveness. Currently, it remains one of the most common birth control options. [2] [3] [4] A better understanding of female hormones started at the beginning of the 20th century, when the first ovarian extracts independently were discovered in Vienna and Paris. 5, 6 In 1919, Haberlandt launched studies showing that transplants of ovarian tissues (now known to produce progesterone) are able to induce sterility in rabbits and mice. [5] [6] [7] Later in 1930, Reiprich assigned anti-fertility action of the estrogens to pituitary inhibition. 5, 6 In 1931, Haberlandt furthered his hormonal research by showing that ovarian and placental tissue hormones were the means for temporary fertility inhibition and, thus birth control. [5] [6] [7] Testing of possible ovulation-inhibitory effects continued in clinical trials in Mexico City, which eventually led to an invention of a hormonal oral contraceptive (OC) by Pincus. 7, 8 Enovid, the first commercially available combined oral contraceptive (COC), containing 150 mg of mestranol and 9.85 mg of norethynodrel, was introduced as a combination of progesterone and estrogen. 7, 9 The pill was first approved for menstrual regulation by the Food and Drug Administration (FDA) in 1957 and later in 1959 for contraceptive use. 8 Being 99.7% effective with perfect use (92% effective with typical use), COCs remain a popular and satisfying method for preventing pregnancy. 10 The first hormonal contraceptive (HC) implants were approved for use in the United States, in 1990. 11 They were first developed as 6 rods inserted under the skin, which gradually released the progestin hormone levonorgestrel into the surrounding tissue. The newest form of HC implants is a single-rod implant. Within the past decade, further research in hormonereleasing technology has led to the development of several birth control products including, but not limited to, injectable forms, vaginal rings, nasal sprays, skin patches, and gels.
Types, Generations, and Mechanism of Action
Hormonal contraception affects the endocrine system. Estrogens and progestins are both steroid hormones. The market offers many HC brands with varying hormone concentrations and different hormone delivery methods. Currently, the daily COCs remain one of the most popular and reliable methods of birth control. 10 Naturally occurring sex steroids are not active when taken orally. However, the addition of an ethinyl group to estradiol significantly increases estrogen absorption into the blood stream. This principle led to the development of ethinyl estradiol in 1964. Currently, ethinyl estradiol is the only estrogen in COCs produced commercially. 9, 12 Current OCs are primarily composed of either estrogen and progesterone or progestogen only. Estrogen and progesterone in COCs are marketed as 2 main types, monophasic and multiphasic. Monophasic COCs provide a regular dose of hormones that remain constant throughout the month. Multiphasic COCs, however, are tailored to provide hormones in varying amounts throughout the menstrual cycle. The hormone level can be administered in either a biphasic or triphasic mode, which adjusts the hormone concentration for each pill taken daily. Some more recent COCs also have estrogen-alone pills added instead of a full placebo week (the fourth, noncontraceptive week during which time the woman had withdrawal bleeding).
Since the introduction of OCs, hormonal contraception research has rapidly progressed to the development of the second and third generations of OCs. First-generation OCs contained higher levels of estrogen and were associated with an elevated risk of thrombosis. Second-generation OCs contained different progestins (levonorgestrel) to act in combination with lower dose estrogen (ethinyl estradiol) to provide contraceptive benefits. Third-generation contraceptives were later introduced, which contained newer progestins (desogestrel, gestodene, norgestimate, and drosperinone). Progestin suppresses ovulation with secondary effects on sperm penetration.
Hormonal Contraceptive Effect on Blood Coagulation Cascade
Initially, it was believed that COC use would not change the hemostatic balance, however, early studies show an increased risk of thrombosis. 13 More recent studies show that COCs affect many coagulation factor proteins involved in homeostasis. For example, COCs decrease protein S and antithrombin, leading to a prothrombotic state. These alterations can have drastic cardiovascular implications leading to increases in coronary heart disease, stroke, pulmonary embolism, venous thrombosis (VT), and sometimes death. [13] [14] [15] [16] [17] Although the risk factors for thrombosis depend on the site of impact, either the arterial or venous system, the mechanism of action remains the same. According to the Virchow triad, reduced blood flow, changes in vessel wall, and changes in coagulation parameters all result in potential for thrombus formation. 16 Complications arise when the cardiovascular system becomes hypercoaguable. 16, 17 The main risk factors for VT are static blood flow and hypercoagulability. Endothelial damage and platelet activation play a crucial role in arterial thrombus formation. For both venous and arterial thrombosis, there is likely a combination of genetic and acquired risk factors.
Estrogen and Progestogen Role in Thrombosis
Following the introduction of first-generation COCs, it was found that a high level of estrogen was associated with myocardial infarction (MI), ischemic stroke (IS), and VT. An increased risk of thrombosis was also observed in men taking estrogen therapy for sexual reassignment. 15 Over time, to reduce thrombotic complications, the accepted dose of estrogen in COCs was reduced from 150 to 20 mg; however, the risk was not eliminated. 15 A 10-fold increased risk of VT in COC users was found in pills containing >50 mg ethinyl estradiol and a 4-fold increased risk for pills containing <50 mg ethinyl estradiol. 18 Published studies 19, 20 show an increased risk of thrombosis in users of third-generation COCs containing the newest progestins (ie, desogestrel and gestodene). A recent metaanalysis confirmed that the odds of VT for third-generation COC users was 1.7 as compared to second-generation COCs. 21 The higher risk of VT did not subside after adjusting for other factors or selected subgroups. It is not clear what effect, if any, differing combinations of estrogens and progestins have on arterial thrombosis. Rosendaal et al 15 concluded that COCs with 30 mg ethinyl estradiol should be the first choice considered for birth control. In addition, because of the increased risk of VT, third-generation COCs should be avoided. 15 The safest option to decrease the risk of VT, as suggested by van Hylckama Vlieg et al, 22 is a COC containing levonorgestrel combined with a low dose of estrogen.
Prothrombotic Risk Factors
Endogenous prothrombotic risk factors are considered an exclusion criterion for estrogen-containing HC use. These include lupus anticoagulant, antithrombin deficiency, protein C (PC) deficiency, protein S (PS) deficiencies, factor V Leiden, and the prothrombin 20210A mutation. Antiphospholipid syndrome is defined by the persistent presence of antibodies against phospholipids (eg, anticardiolipin, anti-b-glycoprtein 1, antiphosphatidylserine) that are associated with multiple venous and arterial thromboembolic events at an early age as well as with thrombocytopenia and fetal loss. 23 Simioni et al, 24 performed a retrospective cohort study and revealed that among carriers of antithrombin, PC, or PS deficiencies, the use of COCs increased the risk of thrombosis (RR: 8.3, 6.4, and 8.2, respectively). The use of HC enhances the already elevated risk of VT, related to prothrombin 20210A or factor V Leiden. 25 Normally, activated PC (APC) inactivates active factor V, reducing the pathway of thrombus generation. However, in carriers of a factor V Leiden mutation, this process is highly impaired, leading to the existence of prothrombotic state. Interestingly, COCs containing third-generation progestogens such as desogestrel and gestodene increase the resistance to APC. 16, 17 Leiden mutation was first shown by Bertina et al, 26 as a point mutation in the factor V gene that leads to APC resistance. Carriers of this mutation downregulate activated factor V and subsequently display enhanced thrombin generation. Activated PC resistance without the presence of factor V Leiden is an independent risk factor for VT. Rosing et al 16, 17 reported that about 5% of the Western-European population carries APC resistance. Thus, it became important to develop a test to assess resistance to APC. The first APC resistance test was developed in 1997. 16 The test determined the response to APC in plasma (when extrinsic pathway is initiated) by measuring the effect of APC on the time integral of thrombin formation. Factor V Leiden is detected with this test. Moreover, the test was sensitive to COCs. 16 Published literatures have shown that plasma samples obtained from participants using COCs are considerably more resistant to APC than plasma from non-COC users. 16, 17, 27, 28 Furthermore, plasma samples obtained from third-generation COC users were significantly more resistant to APC than the plasma of the secondgeneration COC users. 16, 17, 29 It is hypothesized that COCs may cause acquired APC resistance. 16, 17, 27, 28 A high level of homocysteine in plasma is believed to be another predisposing factor for thrombosis, especially for recurrent VT and stroke, due to inhibition of PC activation and promotion of endothelial dysfunction. 30 However, a study conducted by Cauci et al 31 did not find an elevated homocysteine level among COC users.
There are published studies suggesting the association between COC use and prothrombotic factor XIII gene variations with the risk of IS. Pruissen et al 32 conducted a population-based caseÀcontrol study of 190 women with a history of either IS or cardiovascular disease and 767 women without cardiovascular disease to study the relationship between factor XIII gene variation and IS. The additive effect of COC use and factor XII gene mutation on the risk of IS was also analyzed. Activated coagulation factor XIII is involved in cross-linking of the fibrin clot by transglutaminase reactions between fibrin residues (lysine and glutamine). Although an increase in plasma concentration of this factor increases thrombotic risk, the effect seems to be depending on several other plasma protein concentrations such as thrombin, prothrombin, fibrinogen, and fibronectin. Different genetic variations of coagulation factor XIII appeared to affect coagulation system as well. COC users carrying mutant allele 204Phe of factor XIII gene have shown a 20-fold increased risk of IS compared to nonusers. 32 
Changes in Coagulation Markers Due to HC Use
Hoibraaten et al, 33 conducted a study including 140 women with a history of VT looking at the effect of hormonal therapy on hemostatic parameters. The biochemical markers found to be in a prothrombotic state were thrombin generation with increased levels of prothrombin fragments, throm-binÀantithrombin complexes, and D-dimer. The levels of fibrinogen, factor VIII, and factor VII did not change, but the activation of factor VII was shown to be significantly lower. The most significant changes occurred with coagulation inhibitors such as a 10% decrease in antithrombin and PC and a 15% decrease in tissue factor pathway inhibitor (TFPI) activity. The decrease in TFPI level was predictive for activated coagulation. 13 Roell et al, 12 conducted a cross-sectional study and found significant decrease in levels of international normalized ratio, activated thromboplastin time, and increase in plasminogen, fibrin degradation products, and plasmin/antiplasmin complex in women taking COCs. This coagulation activation is counterbalanced by a concurrent activation of fibrinolytic inhibitors, indicating active fibrinolysis. In the study conducted by Scarabin et al, 34 active fibrinolysis was shown by increased levels of antithrombin, t-PA antigen level, and fibrinolytic capacity.
A study conducted by Norris et al 14 investigated both components of COCs on hemostatic variables. Healthy women with no history of thromboembolic disease were randomly assigned to 1 of 3 different monophasic COCs (ie, 30 mg ethinyl estradiol/150 mg desogestrel, 20 mg ethinyl estradiol/150 mg desogestrel, and 30 mg ethinyl estradiol/75 mg gestodene). Both treatment duration and type of COC affected hemostatic variables. Factor X activity was not affected by the type of the COC, but it was significantly higher with longer treatment duration. In general, COCs treatment was found to cause elevation in fibrinogen levels, plasminogen activity, and D-dimer level. The effect on factors VII and X was reduced by reducing the dose of ethinyl estradiol from 30mg to 20 mg. Thus, the authors concluded that low-dose COCs leads to activation of both coagulation and anticoagulation systems. Changes in concentrations and activity of coagulation factors, including increased levels of factors II, VII,VIII, and X, were found in many other studies. [36] [37] [38] Walter et al, 39 conducted a small study of hemostatic response in users and nonusers of COCs during exercise. When compared to controls, women using COCs generally had a larger increase in levels of thrombin and fibrin formation. Thus, it was concluded that COCs' procoagulant effect may be harder to identify at rest but may become much more evident in conjunction with exercise. However, the study does not necessarily represent a typical cross-section of women on COCs, due to a small sample size and a younger age range of COC users.
Platelets play a critical role in the coagulation cascade process. Women display increased platelet function and higher aggregation activity during the third week of their menstrual cycle. 40 Feuring et al, 41 showed that platelets are more activated in the luteal phase (when progesterone is the main hormone), when compared to the follicular phase (when estrogen is crucial). Studies have shown that platelet aggregating activity is much higher in COC users when compared to nonusers of COCs. 12, 40 Roell et al, 12 conducted a cross-sectional study in healthy young women not taking COCs in the follicular and luteal phase compared to those taking different types of monophasic COCs. The results indicated that COCs decrease PFA-100 closure time, which may be mediated by the progestogen level, regardless of the estrogen level. There was a correlation between decreased PFA-100 closure time and increased progesterone level during the menstrual cycle in non-COC users; however, there was a wide variation between individuals. 12 Another important contributor to platelet function is von Willebrand factor (vWF), which is reported to be higher in participants taking COCs. 12 A study conducted by Johnson et al 42 did not reveal any changes in the levels of vWF among the users of COCs versus transdermal contraceptives. Platelets are also activated via fibrinogen binding to glycoprotein (GP) IIb/ IIIa surface receptors. Cahill et al 43 studied the effects of COCs on platelet GP IIb/IIIa receptor activation and found no significant relation between COC use and GP IIb/IIIa activation. However, increased platelet affinity to fibrinogen was found in older participants. 43 Furthermore, higher fibrinogen concentrations were found in COC users compared to control participants in some studies 27, 28, 42, 44 but not in others. 12 Alterations in the balance between proaggregatory and antiaggregatory prostanoids were observed in women taking third-generation progestogens with ethinyl estradiol (ie, 75 mg gestodene or 150 mg desogestrel combined with 30 mg ethinyl estradiol) explained by whole blood platelet aggregation. 45 The increased platelet aggregation in the study was inhibited by the thromboxane synthetase inhibitor, dazmegrel. Therefore, it was suggested that platelet activation among COC users may be mediated by an activation of the platelet cyclooxygenase enzyme. Inhibition of thromboxane synthetase causes increased antiaggregatory prostaglandins (prostaglandins I2 and E2) from platelet-derived endoperoxides. Consequently, inhibitors of thromboxane synthetase may counteract the aggregatory effects of COCs. 45 Another important physiological inhibitor of blood coagulation that has been attracting attention is TFPI. Previously, it was shown that immune depletion of TFPI, in rabbits, significantly decreases the threshold, triggering coagulation by tissue factor and induction of disseminated intravascular coagulation. 46 Dahm et al 47 studied the influence of hormonal state on TFPI anticoagulant activity and its importance in causing thrombosis. The study compared 474 patients with deep vein thrombosis (DVT) versus 474 sex-and agematched controls. It was shown that hormonal state had an explicit effect on the coagulation system. The use of COC was found to be associated with low levels of TFPI anticoagulant activity. In a study by van Vliet et al, 48 levels of TFPI were found to be significantly lower in users of third-generation COCs in comparison to second-generation.
Metabolic Effects of HCs
Levels of triglycerides, cholesterol, low-density lipoproteins (LDL), high-density lipoproteins (HDL), glucose, insulin, and C-reactive protein (CRP) may all be significantly altered due to COCs. Studies have shown that COC use is associated with higher levels of total cholesterol, LDL, triglycerides, in conjunction with decreased levels of HDL. 31, 49 Glucose levels in COC users were found to be even lower than in nonusers, which may be attributed to higher levels of insulin. 50 
Atherosclerosis is considered a chronic inflammatory disease with lesions representing complex interactions between nonimmune cells (endothelial cells and vascular smooth muscle cells), immune cells (macrophages and T-lymphocytes)
, and different inflammatory mediators. 51 Atherosclerosis is one of the most important predisposing risk factors for arterial thrombotic events such as MI and IS. One of the established inflammation markers is CRP, which decreases endothelial progenitor cell survival and differentiation. Level of highsensitivity CRP in COC users comparing to non-COC users was found to be higher, 52, 53 range from 1.0 to 10.0 mg/L, correlating to intermediate and high risk of cardiovascular disease. 31 Recent evidence suggests a strong association between COC use and the onset of proinflammatory state. It also significantly decreases nitric oxide synthesis. 54 In a study conducted by van Rooijen et al, 55 the serum levels of CRP increased after 2 months of COC use. More pronounced effects were present with third-generation COCs (34% of women reached high-risk CRP level) and less pronounced effects with second-generation COCs (20% of women reached high-risk CRP level). However, the study conducted by Silvestri et al 56 suggested that increased levels of CRP in plasma, associated with hormonal therapy, may not be due to inflammation but rather direct stimulation of hepatic CRP production. Vitale et al 53 studied interleukin (IL)-6, an inflammation-derived principal modulator of hepatic CRP production and found a greater sensitivity in assessing the link between COCs and inflammation. In the study, hormonal therapy increased IL-6 levels with a decrease in endothelial function. Thus, it was concluded that plasma CRP levels have a prognostic significance only in association with an increased level of IL-6. Kluft et al, 57 conducted studies to analyze proinflammatory effects of estrogens during the use of COCs and identified a strong positive correlation between CRP and ceruloplasmin (a marker of inflammation in acute phase). Moreover, a positive correlation of ceruloplasmin with fibrinogen, vWF, and factor VIII levels was observed.
Elevated white cell counts were also found to have a statistically significant association with the use of COCs as investigated by Coronary Artery Risk Development in Young Adults (CARDIA) investigators. 58 Morin-Papunen et al 59 confirmed this association in their published study.
Risk Factors for MI and Stroke Among HC Users
The first report of COC-use-associated thrombosis was published in 1961, followed by the first report for MI in 1963. 60 Associations between COC use and stroke were first published in 1968 (for IS) 61 and 1973 (for hemorrhagic stroke). 62 A 5-fold increased risk of MI among COC users, as well as a 3-fold increased risk of IS and a 1.5-to 2-fold increased risk of hemorrhagic stroke, were recently shown in a multicenter study conducted by the World Health Organization (WHO). 15 Several studies have also shown that MI is particularly high among COC users who smoke or are hypertensive. The use of COCs with low dose of estrogen and progestin components is preferred to minimize associated cardiovascular risk factors. Although the development of lower estrogen doses and altered progestin levels have led to fewer cardiovascular complications, adverse effects on coagulation system and metabolic parameters remain a concern. 63 Mant et al, 64 conducted a large cohort study (recruiting 17 032 women) with a follow-up period of 26 years. The study found a significant association between current or past COC use and MI among heavy smokers (!15per day). The study also found a higher risk of IS for current COC users only, regardless of smoking history.
Hypertension is a crucial factor affecting the cardiovascular disease mortality and morbidity rate. A systematic review conducted by Curtis et al 65 concluded that deaths from cardiovascular events among women with hypertension increased from 29.8 to 63.4 per million to 130 to 306 per million between ages 20 to 24 and 40 to 44, respectively. Odds ratio (OR) for IS among hypertensive COC users was found to fall in range between 3.1 and 14.5 compared to normotensive non-COC users. The risk of acute MI among hypertensive COC users was significantly higher comparing to normotensive non-COC users with OR ranging from 6 to 68.
Some studies from the United Kingdom and the United States show no significant association between MI and COC use. 66, 67 However, the large multinational WHO study showed an increased risk of MI in users of low-dose COCs. Among COC users, the attributable risk of MI for women younger than 35 years of age was 2.7 and 34.9 per million for nonsmokers and smokers, respectively. The risk of MI for women 35 years of age or older was increased to 31.0 and 396.2 per million for nonsmokers and smokers, respectively. 68 Sidney et al 69 have found no association between low-dose COC and increased risk of MI. 69 The study was based on a less rigorous screening than current standards to detect cardiovascular risk factors. The WHO study found no increased risk of using COCs by women with normal blood pressure that do not smoke. Other studies have shown an increased risk of MI for older COC users and smokers. 66, 67, [69] [70] [71] [72] The mortality attributable to COC use among smokers younger than age 35 is 1 per 100 000. The mortality rate significantly increases to 1 per 7000 for smokers older than 35 years of age. In comparison, nonsmokers under the age of 35 have a mortality risk estimated as 1 per 250 000. 70 One of the largest case-controlled studies among young women, conducted by Tanis et al 71 showed that the risk of MI for those with prothrombotic mutations was more than 70% higher than for those who did not have this defect. Interaction between these mutations and COC use, with regard to the risk of MI, was not found. It was concluded that women with prothrombotic mutations have an increased risk of MI, but this risk does not increase with the use of COCs.
Some published studies suggest that second-generation COCs may not be associated with increased risk of IS only among young women with no history of smoking, cardiovascular risk factors, and hypertension. 67 The study conducted by the WHO found that in developing countries the risk of IS in second-generation COCs users was increased (OR: 3.38, 95% CI: 2.23-5.13), while third generation OCs users did not reveal an increased risk (OR: 1.18, 95% CI: 0.24-5.86). 67 No significant difference between second and third generations of COCs was found in regard to hemorrhagic stroke. Slooter et al 25 conducted a large population-based, caseÀcontrol study of women of reproductive age. The study focused on the association between prothrombotic conditions and IS. It found that carriers of factor V Leiden mutation and methyltetrahydrofolate reductase 677TT genotype have an increased risk of IS. This risk is further elevated in combination with COC use and/or smoking. 25 
Venous Thrombus
In 1998, the WHO committee concluded that the risk of VT for OCs users is 3 to 6 times higher than that of nonCOC users. 73 In the 1990s, it was suggested that the type of progestin in combination with estrogen has an effect on the risk of thrombosis. Recently, third-generation progestins (gestodene and desogestrel) caused a 2-fold increased risk of VT as compared to second-generation COCs (levonorgestrel and norgestrel). 73 This was discovered by 2 large caseÀcontrol studies, 74, 75 the WHO Collaborative Study of Cardiovascular disease and Steroid Hormone Contraception with more than 4100 women recruited from Asia, Africa, Latin America, and Europe and the Transitional Study on COCs and the Health of Young Women with more than 2200 women recruited from 10 medical centers in the United Kingdom and Germany. Users of third-generation COCs had an increased risk of VT (OR 4.8, 95% CI: 3.4-6.7) when compared to second-generation COC users (OR 3.2, 95% CI: 2.3-4.3). 75 Thus, third-generation COC users had a 1.5-to 2.7-fold increased risk of VT when compared to users of second-generation COCs and 4.8 to 9.4 times higher risk when compared to nonusers. (Table 1) 
Conclusion and Recommendations
Since the first HC became available, it quickly became one of the most popular methods of birth control, with currently over 100 million female users. 63 The use of HCs carries its own risks and benefits. Effective fertility control, favorable effect on dysmenorrhea, and protection against osteoporosis are among the important benefits of using HCs. The review of the literature reveals conflicting outcomes related to the risk of HC use on cardiovascular events. However, many clinical implications and effects of hormones on coagulation markers seem to be evident. Resistance to ACP, increased markers of activated coagulation system and fibrinolysis, and activation of platelets are important changes in blood chemistry, which result from the use of COCs. Moreover, COC use in the presence of genetic factors such as prothrombotic mutations significantly increases the risk of cardiovascular events. Alternative HC methods should be considered for women with high risk of thrombotic events. Thus, a personal history of thrombosis, family history of cardiovascular disease, and prothrombotic anomalies, obesity, smoking, and history of hypertension should be considered when initiating the use of HCs. Future studies are warranted to better identify blood biomarkers associated with increased risk of vascular events among HC users, particularly for newer products such as progestin-only HCs. Although the risk of thrombotic cardiovascular events due to HC use has been substantially reduced since their inception, the quest for developing safer methods of birth control continues.
